Literature DB >> 27227503

Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy.

Javier Benito, Beatriz P Monteiro, Francis Beaudry, Anne-Marie Lavoie, B Duncan X Lascelles, Paulo V Steagall.   

Abstract

OBJECTIVE To evaluate pharmacokinetics of bupivacaine after IP administration to cats undergoing ovariohysterectomy. ANIMALS 8 healthy cats. PROCEDURES Anesthesia was induced with propofol and maintained with isoflurane. Buprenorphine (0.02 mg/kg, IV) and meloxicam (0.2 mg/kg, SC) were administered. A 20-gauge catheter was inserted into a jugular vein for blood sample collection. A ventral midline incision was made, and a solution of 0.5% bupivacaine (2 mg/kg) diluted with an equal volume of saline (0.9% NaCl) solution (final concentration, 0.25% bupivacaine) was injected into the peritoneal space over the right and left ovarian pedicles and caudal aspect of the uterus before ovariohysterectomy. Cats were monitored for signs of bupivacaine toxicosis. Venous blood samples (2 mL) were collected before (time 0) and 2, 5, 10, 15, 20, 30, 60, 120, and 240 minutes after bupivacaine administration. Plasma bupivacaine concentrations were determined with a liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were determined by data plotting followed by analysis with a noncompartmental model. RESULTS No signs of bupivacaine toxicosis were observed. Maximum bupivacaine plasma concentration was 1,030 ± 497.5 ng/mL at a mean ± SD value of 30 ± 24 minutes after administration. Mean elimination half-life was 4.79 ± 2.7 hours. Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively. CONCLUSIONS AND CLINICAL RELEVANCE Intraperitoneal administration of bupivacaine resulted in concentrations that did not cause observable toxicosis. Studies to investigate analgesic effects for this technique in cats are warranted.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27227503     DOI: 10.2460/ajvr.77.6.641

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Successful treatment of local anaesthetic toxicity using intralipid 20% emulsion following intrathoracic bupivacaine overdose in a cat.

Authors:  Sarah Caulfield; Erica Tinson; Rachael Birkbeck
Journal:  JFMS Open Rep       Date:  2022-06-23

2.  Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy.

Authors:  Javier Benito; Beatriz Monteiro; Francis Beaudry; Paulo Steagall
Journal:  Can J Vet Res       Date:  2018-04       Impact factor: 1.310

3.  A retrospective study of anesthesia for subcutaneous ureteral bypass placement in cats: 27 cases.

Authors:  Geneviève C Luca; Beatriz P Monteiro; Marilyn Dunn; Paulo V M Steagall
Journal:  J Vet Med Sci       Date:  2017-04-20       Impact factor: 1.267

4.  Analgesic Efficacy of Bupivacaine or Bupivacaine-Dexmedetomidine After Intraperitoneal Administration in Cats: A Randomized, Blinded, Clinical Trial.

Authors:  Javier Benito; Marina C Evangelista; Graeme M Doodnaught; Ryota Watanabe; Guy Beauchamp; Beatriz P Monteiro; Paulo Steagall
Journal:  Front Vet Sci       Date:  2019-09-13

5.  Clinical applicability of the Feline Grimace Scale: real-time versus image scoring and the influence of sedation and surgery.

Authors:  Marina C Evangelista; Javier Benito; Beatriz P Monteiro; Ryota Watanabe; Graeme M Doodnaught; Daniel S J Pang; Paulo V Steagall
Journal:  PeerJ       Date:  2020-04-14       Impact factor: 2.984

6.  Pharmacokinetics of Bupivacaine Following Administration by an Ultrasound-Guided Transversus Abdominis Plane Block in Cats Undergoing Ovariohysterectomy.

Authors:  Marta Garbin; Javier Benito; Hélène L M Ruel; Ryota Watanabe; Beatriz P Monteiro; Petra Cagnardi; Paulo V Steagall
Journal:  Pharmaceutics       Date:  2022-07-25       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.